# NEOK Bio

> NEOK Bio is a Palo Alto-based clinical-stage biotechnology company developing bispecific antibody drug conjugates (ADCs) for solid tumors. Founded and led by physician-executive Mayank Gandhi and backed by Korean antibody specialist ABL Bio, NEOK launched from stealth in November 2025 with a $75 million Series A. Its dual-targeting approach binds two complementary tumor antigens at once, aiming to widen the therapeutic window and overcome the resistance and toxicity limits of conventional single-target ADCs. The company's two lead programs, NEOK001 (ROR1/B7-H3) and NEOK002 (EGFR/MUC1), both cleared FDA IND review in early 2026 and are headed into Phase 1 studies.

- **Founded:** 2025
- **Headquarters:** Palo Alto, California, United States
- **Founders:** Mayank Gandhi (Co-Founder & Chief Executive Officer)
- **Team size:** ~4 employees (2025-2026)
- **Products:** NEOK001 (formerly ABL206), NEOK002 (formerly ABL209)
- **Notable:** Raised a $75 million Series A and launched from stealth in November 2025., Advanced two distinct bispecific ADC programs into the clinic within about a year., Secured FDA IND clearance for NEOK002 (EGFR/MUC1) in March 2026.

## Products & services

- **NEOK001 (formerly ABL206)** — A first-in-class bispecific antibody drug conjugate targeting ROR1 and B7-H3, two proteins involved in tumor growth, developed for thoracic, gastrointestinal, and gynecological solid tumors. Cleared FDA IND review with Phase 1 planned for mid-2026.
- **NEOK002 (formerly ABL209)** — A bispecific antibody drug conjugate targeting EGFR and MUC1, built on a RenLite bispecific antibody licensed from Biocytogen, designed to offer improved efficacy and safety over monospecific EGFR- or MUC1-directed ADCs. FDA IND cleared March 2026; Phase 1 planned for Q2 2026.

## Achievements

- Raised a $75 million Series A and launched from stealth in November 2025.
- Advanced two distinct bispecific ADC programs into the clinic within about a year.
- Secured FDA IND clearance for NEOK002 (EGFR/MUC1) in March 2026.
- Secured FDA IND clearance for NEOK001 (ROR1/B7-H3) ahead of a mid-2026 Phase 1 start.
- Assembled a board pairing US oncology-industry leadership with ABL Bio's antibody-engineering founders.

## Latest updates

- **2026-03** — NEOK Bio secured FDA IND clearance for NEOK002, its EGFR/MUC1 bispecific ADC, with a Phase 1 study planned for Q2 2026 and initial data expected in 2027.
- **2026-03** — Partner Biocytogen announced the NEOK002 IND clearance, highlighting the RenLite-derived bispecific antibody it licensed to NEOK in 2024.
- **2025-11** — NEOK Bio launched from stealth with a $75 million Series A led by ABL Bio to advance next-generation bispecific ADCs in oncology.

## Links

- Website: https://neokbio.com
- LinkedIn: https://www.linkedin.com/company/neok-bio

---

Profile page: https://yespress.io/neok-bio
Published by YesPress — https://yespress.io
Last updated: 2026-07-11